Literature DB >> 16934915

Marker vaccine strategies and candidate CSFV marker vaccines.

Xiao-Nan Dong1, Ying-Hua Chen.   

Abstract

Classical swine fever (CSF) is an economically important highly contagious disease of swine worldwide. Classical swine fever virus (CSFV) is its etiological agent, and the only natural hosts are domestic pigs and wild boars. Although field CSFV strains vary in the virulence, they all result in serious losses in pig industry. Highly virulent field strains generally cause acute disease and high mortality; moderately virulent field strains raise subacute or chronic infections; postnatal infection by low virulent field strains produces subclinical infection and mortality in the new-born piglets. CSFV can cross the placental barrier, and this transplacental transmission usually results in mortality of fetuses and birth of congenitally infected pigs with a late-onset disease and death. Two main strategies to control CSF epidemic are systematic prophylactic vaccination with live attenuated vaccines (such as C-strain) and non-vaccination stamping-out policy. But neither of them is satisfying enough. Marker vaccine and companion serological diagnostic test is thought to be a promising strategy for future control and eradication of CSF. During the past 15 years, various candidate marker vaccines were constructed and evaluated in the animal experiments, including recombinant chimeric vaccines, recombinant deletion vaccines, DNA vaccines, subunit vaccines and peptide vaccines. Among them, two subunit vaccines entered the large scale marker vaccine trial of EU in 1999. Although they failed to fulfil all the demands of the Scientific Veterinary Committee, they successfully induced solid immunity against CSFV in the vaccinated pigs. It can be expected that new potent marker vaccines might be commercially available and used in systematic prophylactic vaccination campaign or emergency vaccination in the next 15 years. Here, we summarized current strategies and candidate CSFV marker vaccines. These strategies and methods are also helpful for the development of new-generation vaccines against other diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934915     DOI: 10.1016/j.vaccine.2006.07.033

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Generation and Efficacy Evaluation of a Recombinant Pseudorabies Virus Variant Expressing the E2 Protein of Classical Swine Fever Virus in Pigs.

Authors:  Yimin Wang; Jin Yuan; Xin Cong; Hua-Yang Qin; Chun-Hua Wang; Yongfeng Li; Su Li; Yuzi Luo; Yuan Sun; Hua-Ji Qiu
Journal:  Clin Vaccine Immunol       Date:  2015-08-26

2.  Prokaryotic expression and purification of highly soluble partial glycoprotein erns of Indian strain of classical Swine Fever virus.

Authors:  A Ahuja; A Sen; R Yogisharadhya; K K Rajak; S B Shivachandra
Journal:  Indian J Virol       Date:  2012-09-25

3.  Genetic diversity and positive selection analysis of classical swine fever virus isolates in south China.

Authors:  Haiyan Shen; Jingjing Pei; Jialin Bai; Mingqiu Zhao; Chunmei Ju; Lin Yi; Yanmei Kang; Xuetao Zhang; Lijun Chen; Yinguang Li; Jiaying Wang; Jinding Chen
Journal:  Virus Genes       Date:  2011-06-04       Impact factor: 2.332

4.  Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus.

Authors:  Helin Li; Pengbo Ning; Zhi Lin; Wulong Liang; Kai Kang; Lei He; Yanming Zhang
Journal:  J Biosci       Date:  2015-03       Impact factor: 1.826

Review 5.  Classical swine fever in India: current status and future perspective.

Authors:  Vinod Kumar Singh; Kaushal Kishore Rajak; Amit Kumar; Sharad Kumar Yadav
Journal:  Trop Anim Health Prod       Date:  2018-05-04       Impact factor: 1.559

6.  Complete genome sequence of attenuated low-temperature Thiverval strain of classical swine fever virus.

Authors:  Yunfeng Fan; Qizu Zhao; Yun Zhao; Qin Wang; Yibao Ning; Zhongqiu Zhang
Journal:  Virus Genes       Date:  2008-04-10       Impact factor: 2.332

7.  Multiple linear B-cell epitopes of classical swine fever virus glycoprotein E2 expressed in E.coli as multiple epitope vaccine induces a protective immune response.

Authors:  Bin Zhou; Ke Liu; Yan Jiang; Jian-Chao Wei; Pu-Yan Chen
Journal:  Virol J       Date:  2011-07-30       Impact factor: 4.099

8.  Efficiency of spatio-temporal vaccination regimes in wildlife populations under different viral constraints.

Authors:  Martin Lange; Stephanie Kramer-Schadt; Hans-Hermann Thulke
Journal:  Vet Res       Date:  2012-04-24       Impact factor: 3.683

9.  Generation and first characterization of TRDC-knockout pigs lacking γδ T cells.

Authors:  Bjoern Petersen; Robert Kammerer; Antje Frenzel; Petra Hassel; Tung Huy Dau; Roswitha Becker; Angele Breithaupt; Reiner Georg Ulrich; Andrea Lucas-Hahn; Gregor Meyers
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

10.  Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine.

Authors:  Erlinda Fernández; Jorge R Toledo; Lídice Méndez; Nemecio González; Francisco Parra; José M Martín-Alonso; Miladys Limonta; Kosara Sánchez; Ania Cabrales; Mario P Estrada; Alina Rodríguez-Mallón; Omar Farnós
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.